View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 23, 2022

Moderna’s booster shot shows antibody response against Omicron subvariants

The company plans to make regulatory submissions seeking update to the composition of the booster vaccine to mRNA-1273.214.

Moderna has reported latest clinical findings where its bivalent (Omicron) Covid booster candidate, mRNA-1273.214 stimulated potent neutralising antibody responses against the BA.4 and BA.5 subvariants of Omicron.

A 50µg booster dose of mRNA-1273.214 showed such activity a month following dosing in already vaccinated and boosted subjects, irrespective of previous infection.   

Furthermore, the vaccine provided a 5.4-fold enhanced neutralising titers against BA.4/BA.5 above baseline in all subjects irrespective of previous infection and a 6.3-fold in the subset of seronegative subjects. 

Compared to priorly reported neutralising titers against BA.1, nearly three-fold reduced neutralising titers against BA.4/BA.5 were reported.

Neutralising geometric mean titers (GMT) against BA.4/BA.5 A month after an mRNA-1273.214 booster were 941 and 727 in all subjects and seronegative participants, respectively. 

The latest findings supplement data from the ongoing Phase II/III clinical trial in nearly 800 subjects. 

According to the trial data, a 50µg booster dose of mRNA-1273.214 achieved all pre-specified primary endpoints, including superiority in neutralising antibody GMT against Omicron (BA.1), versus a 50µg booster dose of the prototype booster, mRNA-1273. 

In addition, the bivalent booster was found to be well-tolerated, with a reactogenicity and safety profile in line with the prototype booster. 

Based on these data, the company will make regulatory submissions seeking an update to the composition of the booster vaccine to mRNA-1273.214.

Moderna CEO Stéphane Bancel said: “In the face of SARS-CoV-2’s continued evolution, we are very encouraged that mRNA-1273.214, our lead booster candidate for the fall, has shown high neutralising titers against the BA.4 and BA.5 subvariants, which represent an emergent threat to global public health. 

“We will submit these data to regulators urgently and are preparing to supply our next generation bivalent booster starting in August, ahead of a potential rise in SARS-CoV-2 infections due to Omicron subvariants in the early fall.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena